Cargando…

Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test

Preeclampsia remains a leading cause of maternal and perinatal morbidity and mortality. Accurate prediction of preeclampsia risk would enable more effective, risk-based prenatal care pathways. Current risk assessment algorithms depend on clinical risk factors largely unavailable for first-time pregn...

Descripción completa

Detalles Bibliográficos
Autores principales: Kenny, Louise C., Thomas, Grégoire, Poston, Lucilla, Myers, Jenny E., Simpson, Nigel A. B., McCarthy, Fergus P., Brown, Leslie W., Bond, Alison E., Tuytten, Robin, Baker, Philip N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769282/
https://www.ncbi.nlm.nih.gov/pubmed/33370367
http://dx.doi.org/10.1371/journal.pone.0244369
_version_ 1783629289403449344
author Kenny, Louise C.
Thomas, Grégoire
Poston, Lucilla
Myers, Jenny E.
Simpson, Nigel A. B.
McCarthy, Fergus P.
Brown, Leslie W.
Bond, Alison E.
Tuytten, Robin
Baker, Philip N.
author_facet Kenny, Louise C.
Thomas, Grégoire
Poston, Lucilla
Myers, Jenny E.
Simpson, Nigel A. B.
McCarthy, Fergus P.
Brown, Leslie W.
Bond, Alison E.
Tuytten, Robin
Baker, Philip N.
author_sort Kenny, Louise C.
collection PubMed
description Preeclampsia remains a leading cause of maternal and perinatal morbidity and mortality. Accurate prediction of preeclampsia risk would enable more effective, risk-based prenatal care pathways. Current risk assessment algorithms depend on clinical risk factors largely unavailable for first-time pregnant women. Delivering accurate preeclampsia risk assessment to this cohort of women, therefore requires for novel biomarkers. Here, we evaluated the relevance of metabolite biomarker candidates for their selection into a prototype rapid, quantitative Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) based clinical screening assay. First, a library of targeted LC-MS/MS assays for metabolite biomarker candidates was developed, using a medium-throughput translational metabolomics workflow, to verify biomarker potential in the Screening-for-Pregnancy-Endpoints (SCOPE, European branch) study. A variable pre-selection step was followed by the development of multivariable prediction models for pre-defined clinical use cases, i.e., prediction of preterm preeclampsia risk and of any preeclampsia risk. Within a large set of metabolite biomarker candidates, we confirmed the potential of dilinoleoyl-glycerol and heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine to effectively complement Placental Growth Factor, an established preeclampsia biomarker, for the prediction of preeclampsia risk in first-time pregnancies without overt risk factors. These metabolites will be considered for integration in a prototype rapid, quantitative LC-MS/MS assay, and subsequent validation in an independent cohort.
format Online
Article
Text
id pubmed-7769282
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-77692822021-01-08 Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test Kenny, Louise C. Thomas, Grégoire Poston, Lucilla Myers, Jenny E. Simpson, Nigel A. B. McCarthy, Fergus P. Brown, Leslie W. Bond, Alison E. Tuytten, Robin Baker, Philip N. PLoS One Research Article Preeclampsia remains a leading cause of maternal and perinatal morbidity and mortality. Accurate prediction of preeclampsia risk would enable more effective, risk-based prenatal care pathways. Current risk assessment algorithms depend on clinical risk factors largely unavailable for first-time pregnant women. Delivering accurate preeclampsia risk assessment to this cohort of women, therefore requires for novel biomarkers. Here, we evaluated the relevance of metabolite biomarker candidates for their selection into a prototype rapid, quantitative Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) based clinical screening assay. First, a library of targeted LC-MS/MS assays for metabolite biomarker candidates was developed, using a medium-throughput translational metabolomics workflow, to verify biomarker potential in the Screening-for-Pregnancy-Endpoints (SCOPE, European branch) study. A variable pre-selection step was followed by the development of multivariable prediction models for pre-defined clinical use cases, i.e., prediction of preterm preeclampsia risk and of any preeclampsia risk. Within a large set of metabolite biomarker candidates, we confirmed the potential of dilinoleoyl-glycerol and heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine to effectively complement Placental Growth Factor, an established preeclampsia biomarker, for the prediction of preeclampsia risk in first-time pregnancies without overt risk factors. These metabolites will be considered for integration in a prototype rapid, quantitative LC-MS/MS assay, and subsequent validation in an independent cohort. Public Library of Science 2020-12-28 /pmc/articles/PMC7769282/ /pubmed/33370367 http://dx.doi.org/10.1371/journal.pone.0244369 Text en © 2020 Kenny et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kenny, Louise C.
Thomas, Grégoire
Poston, Lucilla
Myers, Jenny E.
Simpson, Nigel A. B.
McCarthy, Fergus P.
Brown, Leslie W.
Bond, Alison E.
Tuytten, Robin
Baker, Philip N.
Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test
title Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test
title_full Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test
title_fullStr Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test
title_full_unstemmed Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test
title_short Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test
title_sort prediction of preeclampsia risk in first time pregnant women: metabolite biomarkers for a clinical test
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769282/
https://www.ncbi.nlm.nih.gov/pubmed/33370367
http://dx.doi.org/10.1371/journal.pone.0244369
work_keys_str_mv AT kennylouisec predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest
AT thomasgregoire predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest
AT postonlucilla predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest
AT myersjennye predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest
AT simpsonnigelab predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest
AT mccarthyfergusp predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest
AT brownlesliew predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest
AT bondalisone predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest
AT tuyttenrobin predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest
AT bakerphilipn predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest
AT predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest